Monopar Therapeutics

Monopar Therapeutics has begun submitting its New Drug Application for ALXN1840 to the FDA for Wilson disease treatment, potentially offering a new therapeutic option.

Monopar Therapeutics announced its late-stage candidate, ALXN1840 (tiomolibdate choline), has received Rare Pediatric Disease designation from the FDA for the treatment of Wilson disease.

Monopar Therapeutics announced new Phase 3 FoCus trial data showing ALXN1840 provides superior neurologic and global clinical benefits for Wilson disease patients.

Monopar Therapeutics presented Phase 2 clinical trial results for ALXN1840 in Wilson disease patients at the 2026 EASL International Liver Congress.

Monopar Therapeutics announced positive results from a Phase 2 study published in Hepatology Communications, demonstrating that ALXN1840 significantly improves copper balance in Wilson disease patients.

Monopar Therapeutics announced first quarter 2026 financial results, highlighting progress on its ALXN1840 New Drug Application submission and providing business updates.

Monopar Therapeutics reports Q1 2026 results, detailing progress in its ALXN1840 and radiopharmaceutical programs, alongside financial performance and future funding outlook.

Monopar Therapeutics significantly boosts its cash reserves by $91.9 million and reports clinical progress across its Wilson disease and radiopharmaceutical oncology pipeline.

Monopar Therapeutics Inc. reported an increased net loss for Q2 2025, while advancing its ALXN1840 Wilson disease program towards an NDA filing and progressing its radiopharmaceutical pipeline.

Monopar Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its Wilson disease and radiopharmaceutical programs.

Monopar Therapeutics reported its Q3 2024 financial results, highlighted progress in its radiopharmaceutical programs, and announced the in-licensing of a late-stage Wilson disease drug candidate.

Monopar Therapeutics is focusing on its radiopharmaceutical programs, winding down other programs, and reported a net loss of $3.36 million for the first half of 2024.

Monopar Therapeutics Inc. filed an amended annual report for 2025, correcting an audit report date and providing updated certifications, while revealing a strengthened financial position and ongoing pipeline development.

Monopar Therapeutics reports progress in its Wilson disease and radiopharmaceutical oncology programs, backed by a recent $91.9 million capital raise and extended cash runway through 2027.

Monopar Therapeutics Inc. files its 10-K report for the fiscal year ended December 31, 2024, detailing its financial status and progress in developing ALXN1840 for Wilson disease and its novel radiopharmaceutical programs for oncology.

Monopar Therapeutics Inc.'s 2023 annual report highlights progress in its radiopharmaceutical program and ongoing clinical trials for camsirubicin, while also addressing financial challenges and compliance issues.

Monopar Therapeutics Chief Financial Officer, Quan Anh Vu, has acquired shares through the vesting and settlement of restricted stock units, with a portion withheld for taxes.

Chandler Robinson, CEO and Director of Monopar Therapeutics, reported transactions involving restricted stock units and common stock.

Monopar Therapeutics reports that Chief Operating Officer Andrew Cittadine acquired shares through the vesting and settlement of restricted stock units.

Monopar Therapeutics Director Nicole Sweeny acquired 1,284 stock options with an exercise price of $87.68, vesting in two tranches.

CEO Chandler Robinson acquired 6,732 shares of Monopar Therapeutics common stock through the vesting of restricted stock units.

Monopar Therapeutics Chief Operating Officer Andrew Cittadine acquired 3,514 shares via RSU vesting and withheld 1,571 shares for taxes.

Monopar Therapeutics Inc. has filed a definitive proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission.

Monopar Therapeutics will hold its annual stockholders meeting on June 17, 2025, to vote on director elections, executive compensation, and auditor ratification.

Monopar Therapeutics is asking stockholders to approve a reverse stock split and an amendment to their stock incentive plan at the upcoming annual meeting on August 5, 2024.

Tactic Pharma LLC and its principals have ceased to be beneficial owners of more than five percent of Monopar Therapeutics common stock following a pro rata distribution to its members.

Monopar Therapeutics is repurchasing 550,229 shares of its common stock from Tactic Pharma LLC at $63.6098 per share, contingent on a concurrent public offering.

Key shareholders of Gem Pharmaceuticals LLC, including Monopar Therapeutics and individuals Diane Hendricks and Karl Leo, have entered into a lock-up agreement restricting the sale of their recently distributed common stock until December 31, 2025.

Saturn V Capital Management LP and Xiaoying Tian have reported beneficial ownership of 345,626 shares, representing 5.2% of Monopar Therapeutics Inc.'s common stock.

Adage Capital Management, L.P. has reported beneficial ownership of 6.23% of Monopar Therapeutics' common stock, including shares issuable upon warrant exercise.

AstraZeneca PLC and its subsidiary, Alexion Pharmaceuticals, Inc., reported a 7.8% beneficial ownership stake in Monopar Therapeutics Inc. common stock.

RA Capital Management and its affiliates reported a 9.9% beneficial ownership stake in Monopar Therapeutics Inc., primarily through common stock and pre-funded warrants.

Janus Henderson Group plc and its affiliates report a 19.5% beneficial ownership in Monopar Therapeutics Inc. common stock.

Janus Henderson Group plc and its affiliates have disclosed a significant beneficial ownership stake of 19.2% in Monopar Therapeutics Inc. common stock.